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Introduction: Bone metastasis is a serious complication in patients 
with lung cancer, occurring in up to 40% of patients. Tumor cell–
mediated osteolysis occurs ultimately through induction of RANK 
ligand (RANKL) within the bone stroma although this hypothesis 
has not been tested extensively in the setting of non–small-cell lung 
cancer (NSCLC). By using two novel NSCLC bone metastasis mouse 
models, we examined the effects of RANKL inhibition on osteolysis 
and tumor progression.
Methods: We treated mice bearing skeletal NSCLC tumors with 
osteoprotegerin-Fc (OPG-Fc) to assess whether osteoclast inhibition 
through RANKL inhibition would affect bone metastases at early or 
late stages of bone colonization. Progression of skeletal tumor was 
determined by radiography, longitudinal bioluminescent imaging, 
and histological analyses.
Results: OPG-Fc reduced development and progression of radiographi-
cally evident osteolytic lesions and also significantly reduced skeletal 
tumor progression in both NSCLC bone metastasis models. In the H1299 
human NSCLC bone metastasis model, OPG-Fc plus docetaxel in combi-
nation resulted in significantly greater inhibition of skeletal tumor growth 
compared with either single agent alone. The observed ability of RANKL 
inhibition to reduce NSCLC osteolytic bone destruction or skeletal tumor 
burden was associated with decreases in tumor-associated osteoclasts.
Conclusions: These results demonstrate that RANKL is required 
for the development of tumor-induced osteolytic bone destruction 
caused by NSCLC cells in vivo. RANKL inhibition also reduced 
skeletal tumor burden, presumably through the indirect mechanism 
of blocking tumor-induced osteoclastogenesis and resultant produc-
tion of growth factors and calcium from the bone microenvironment. 
RANKL inhibition also provided an additive benefit to docetaxel 
treatment by augmenting the reduction of tumor burden.
Key Words: RANK ligand inhibition, Osteoprotegerin, Bone 
 metastasis, Osteolysis, Lung cancer.
(J Thorac Oncol. 2014;9: 345–354)
Bone is a common site of metastasis in patients with lung cancer, with up to 40% of lung cancer patients develop-
ing metastases to skeletal sites.1,2 Bone metastases can lead to 
the pathologic destruction of bone and resulting skeletal com-
plications, including increased bone fragility or fracture risk, 
severe bone pain, hypercalcemia, and spinal cord compression 
or other nerve-compression disorders.1–3 The tumor-induced 
bone destruction is mediated by the bone-resorptive action of 
osteoclasts, which are cells exquisitely designed for the degra-
dation of the organic and inorganic component of bone.4
RANK ligand (RANKL) is vital for the formation, func-
tion, and survival of osteoclasts, and several lines of evidence 
indicate an essential role of this factor in the establishment and 
development of skeletal destruction owing to bone metastases.5 
RANKL functions through its cognate receptor RANK, which 
is expressed on osteoclasts and osteoclast precursors, and is 
inhibited by the soluble decoy receptor osteoprotegerin (OPG).6,7 
Metastatic tumor cells cause an up-regulation of RANKL within 
bone stromal cells through diverse signals including interleukin 
(IL)-1β, IL-6, IL-8, IL-11, IL-17, macrophage inflammatory 
protein-1 alpha (MIP1α), tumor necrosis factor-α, parathy-
roid hormone-related protein (PTHrP), and prostaglandin E2 
(PGE2).3 Concomitantly, tumor involvement in the bone may 
also down-regulate local OPG levels in stromal and osteoblastic 
cells in response to PTHrP, IL-1, PGE2, Dickkopf-related pro-
tein 1 (DKK-1), or epidermal growth factor (EGF).8–10 Either 
way, the ratio of RANKL to OPG is increased in the local bone 
microenvironment, leading to focally aggressive osteolytic bone 
destruction. Different tumor types may use distinct signals to 
increase osteolysis through RANKL and/or OPG changes.
Preclinical studies using experimental models of pros-
tate, breast, and lung cancer bone metastases demonstrated that 
RANKL inhibition was associated with the prevention of tumor-
associated bone disease.11–14 Furthermore, locally, high concen-
trations of growth factors and calcium are released in the reactive 
bone microenvironment as a result of  tumor-induced osteoclastic 
action, therefore providing further stimulation of tumor growth 
and survival, a process termed the vicious cycle.3 Previous studies 
on breast and prostate cancer bone metastases have demonstrated 
the ability of RANKL inhibition in reducing skeletal tumor pro-
gression through interruption of the vicious cycle in addition to 
the blockade of osteoclast-mediated bone destruction.15
Recent clinical studies in patients with advanced cancer, 
including lung cancer, have indicated that RANKL inhibition, 
Copyright © 2013 by the International Association for the Study of Lung 
Cancer
ISSN: 1556-0864/14/0903-0345
RANKL Inhibition Blocks Osteolytic Lesions and Reduces 
Skeletal Tumor Burden in Models of Non–Small-Cell Lung 
Cancer Bone Metastases
Robert E. Miller, BS,* Jon C. Jones, BS,* Mark Tometsko, BS,† Michelle L. Blake, PhD,*  
and William C. Dougall, PhD†
*Department of Hematology/Oncology Research, Amgen Inc., Seattle, 
Washington; and †Therapeutic Innovation Unit, Amgen Inc., Seattle, 
Washington.
Disclosure: All authors are current or former employees of Amgen Inc. and 
hold shares of Amgen stock.
Address for correspondence: William C. Dougall, PhD, Amgen Inc., 1201 Amgen 
Court West, Seattle, WA 98119-3105. E-mail: dougallw@amgen.com
ORIGINAL ARTICLE
346 Copyright © 2013 by the International Association for the Study of Lung Cancer
Miller et al. Journal of Thoracic Oncology ®  •  Volume 9, Number 3, March 2014
through the fully human anti-RANKL antibody denosumab, 
reduced the risk of skeletal adverse events and, moreover, was 
associated with improved overall survival when compared 
with zoledronic acid (ZA) in patients with lung cancer.16,17 
It is therefore important to define the mechanisms by which 
RANKL inhibition may reduce skeletal tumor burden in 
lung cancer, specifically. In this study, we describe the devel-
opment of two novel mouse models of non–small-cell lung 
cancer (NSCLC) bone metastasis, and evaluate the effects of 
the RANKL inhibitor human osteoprotegerin-Fc (OPG-Fc), 
either alone or in combination with the chemotherapeutic 
agent docetaxel, on experimental NSCLC-induced osteolytic 
lesions, skeletal tumor burden, and survival.
MATERIALS AND METHODS
Tumor Cell Lines
The human NSCLC cell lines H1975 (CRL-5908) and 
H1299 (CRL-5803; ATCC, Manassas, VA) were transduced 
to express Firefly luciferase (FLuc) and green fluorescent 
protein for bioluminescent imaging (BLI) as described.18 The 
ability of H1299 luciferase–expressing cells to seed and grow 
in bone was enhanced by one round of in vivo passage by iso-
lating green fluorescent protein–/luciferase-expressing cells 
from an osteolytic lesion after intracardiac (IC) challenge. In 
brief, after IC challenge with H1299 luciferase–expressing 
cells, a tumor site was identified by both BLI and the devel-
opment of a radiographic lesion in the tibia of a challenged 
mouse. This location was excised and mechanically disrupted 
and placed in culture. The resultant isolate, which was named 
H1299Luc, resulted in 100% tumor take in the hind limbs 
of all IC-challenged mice, and was used for all subsequent 
experiments described. Cells were cultured in Roswell Park 
Memorial Institute (RPMI) media (Invitrogen, Grand Island, 
NY) with 10% fetal calf serum at 5% carbon dioxide, at 37°C.
Animals for In Vivo Studies
Athymic (R-Foxn1<nu>) nude female mice were 
obtained from Taconic Farms (Germantown, NY) and main-
tained under specific pathogen-free conditions. Purina Rodent 
Chow 5002 (Ralston Purina, St. Louis, MO) or Harlan Teklad 
Rodent Diet #8728C (Madison, WI) and tap water were pro-
vided ad libitum. The laboratory housing the cages provided 
a 12-hour light cycle and met all Association for Assessment 
and Accreditation of Laboratory Animal Care specifications. 
All experiments performed at Amgen Inc. (Thousand Oaks, 
CA) were approved and performed in accordance with guide-
lines set out by the Amgen Animal Use and Care Committee.
IC Model of Bone Metastasis
For the IC model of bone metastasis, 4- to 6-week-old 
mice were injected with 1 × 105 cells in a 100 μl volume into 
the left cardiac ventricle. In vivo BLI of mice was measured 
weekly beginning on the day of tumor challenge with an IVIS 
200 imager (Xenogen, Alameda, CA) as described.18 For stud-
ies using H1975Luc, mice were pretreated with a low–molec-
ular-weight heparin, enoxaparin (Lovenox; Sanofi Aventis, 
Bridgewater, NJ), to prevent thrombotic events. Enoxaparin 
sodium injection was diluted in 0.9% sterile saline to a con-
centration of 1 mg/ml and administered at 10 mg/kg intrave-
nously into the tail vein 10 minutes before IC challenge. On 
the basis of a previously published study using intravenous 
enoxaparin in mice in a small-cell lung carcinoma mouse 
model of metastasis, we have chosen the enoxaparin dose that 
does not change the metastatic distribution of tumor cells.19 
For both the H1299Luc and H1975Luc models, BLI con-
firmed that the majority of the tumor was distributed within 
the skeleton at hindlimbs during the entire study course. Some 
minimal additional tumor was also observed at other skeletal 
sites in the vertebrae and skull.
To examine the effects of OPG-Fc on osteoclast activ-
ity in NSCLC-induced bone destruction, mice bearing 
NSCLC tumors were randomly assigned to three treatment 
groups (n = 10 per group) after IC challenge with either 
H1299Luc or H1975Luc. The treatment groups consisted of 
(1)  phosphate-buffered saline (PBS) thrice weekly subcuta-
neously (SC) beginning on day 1 after tumor challenge; (2) 
human OPG-Fc 3 mg/kg thrice weekly SC beginning on day 
1 after tumor challenge (preventive protocol); and (3) human 
OPG-Fc 3 mg/kg thrice weekly SC beginning on day 7 after 
tumor challenge (established protocol). Mice were imaged 
twice weekly beginning on days 4 to 6 after tumor challenge, 
and images were gated for regions of interest on the hind 
limbs as described.18,20
Animals were monitored weekly for progression of 
osteolytic lesion by digital radiograph (Faxitron, Wheeling, IL). 
Studies were terminated at day 19 and day 27 for H1299Luc 
and H1975Luc, respectively. Serum samples were collected 
at the time of necropsy and frozen at −80°C. Serum tartrate-
resistant alkaline phosphatase 5b (sTRAP5b) levels were mea-
sured by enzyme-linked immunoassay by using MouseTRAP 
Assay (Immunodiagnostic Systems Limited, Bolton, United 
Kingdom). Histological measurements of tumor area were 
performed on hematoxylin-and-eosin–stained sections of tib-
ias and femurs from each mouse and quantified using Osteo 
II software (Bioquant, Nashville, TN) in a blinded manner by 
a pathologist; intrabone tumor area was reported in square 
millimeters. Radiograph lesion areas were calculated using 
MetaMorph Imaging software (Molecular Devices Corporation, 
Downingtown, PA) on randomized blinded images.
To test the effects of combined OPG-Fc and chemo-
therapy on bone lesions and progression of skeletal tumor, 
the H1299Luc IC model was used for combination studies 
because of the greater size of skeletal tumors. Bioluminescent 
signals were detectable in hind limbs within 2 days post-tumor 
challenge, distributed into one of four possible treatment regi-
mens (n = 10 per group) on the basis of rank randomization 
of day 5 BLI signals to normalize the distribution within 
each group. The control regimen comprised PBS (thrice 
weekly, SC) beginning on day 5, plus intraperitoneal (IP) 
saline on post-tumor challenge days 5 and 12. Active treat-
ments included OPG-Fc (3 mg/kg thrice weekly SC) begin-
ning on day 5 (plus IP saline on post-tumor challenge days 5 
and 12); docetaxel only (35 mg/kg IP bolus injection on post-
tumor challenge days 5 and 12) with PBS SC (thrice weekly); 
or docetaxel (35 mg/kg days 5 and 12) combined with 
OPG-Fc (3 mg/kg thrice weekly). Studies were terminated on 
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day 21 post-tumor challenge and histological tumor volume, 
sTRAP5b, radiograph analysis, and histological examination 
of tumor-associated osteoclasts were each performed from 
samples obtained at this time point. For the survival study, the 
cohorts were treated as described above for the combination 
treatments; mice were continually treated according to that 
schedule and monitored until death or until they experienced 
hind limb paralysis or had 20% weight loss (operative defini-
tion of  survival), at which point the mice were euthanized.
Subcutaneous Tumor Model
Twelve-week-old female athymic nu/nu mice were 
injected SC in the flanks with 2 × 106 human H1299Luc or 
H1975Luc cells suspended 1:1 in a mixture of Matrigel (BD 
Biosciences, Bedford, MA). Animals were randomized into 
the following treatment groups (10 mice in each treatment 
group for both H1299Luc and H1975Luc): (1) PBS thrice 
weekly SC beginning on the day of tumor challenge and (2) 
human OPG-Fc 3 mg/kg thrice weekly SC beginning on the 
day of tumor challenge. Tumor dimensions were measured by 
a digital caliper twice weekly. Tumor volumes were calculated 
as [length × (width)2/2].
Human RANK Transduction and Protein  
Expression
Cells were transduced with a retroviral LZRS-pBMNZ 
vector containing a full-length version of human RANK. 
Production of infectious retroviral vector particles was per-
formed in 293-E Phoenix packaging cells as described.21 
Cells were infected with varying amounts of the RANK ret-
roviral construct in the presence of 5 μg/ml Polybrene. Forty-
eight hours after infection, cells were lifted with Versene 
and analyzed by flow cytometry. Surface RANK expression 
was determined by flow cytometry after incubation with 
either 1 μg/ml mouse anti-RANK antibody (M331, N1H8, 
or N2B10; Amgen) or isotype control (anti-AGP3 muIgG1 
clone 4D2; Amgen) in 2% fetal bovine serum followed by 
 allophycocyanin-conjugated anti-mouse secondary antibody. 
Fluorescence was assessed by using a FAScan sorter (BD 
Biosciences, San Jose, CA).
Statistical Analyses
Statistical analyses were performed using JMP7 and 
SAS software (Cary, NC). BLI data were evaluated using a 
repeated-measures model which included the effects of treat-
ment, day, and treatment-by-day interactions. Between-group 
BLI comparisons at individual time points were performed 
using an analysis of variance with a post hoc Dunnett’s test 
used for comparisons between the control and treatment 
groups. Comparisons of survival time were analyzed with the 
Wilcoxon test using JMP7 statistical software (SAS Institute, 
Inc.). A significance level of 0.05 was used for all comparisons.
RESULTS
Development of NSCLC Bone Metastasis  
Models
IC injection of human tumor cell lines into 
 immune-compromised mice is an established model for study-
ing tumor metastasis to bone. We combined IC challenge with 
BLI to develop new models to study the effects of inhibiting 
RANKL specifically on NSCLC-induced bone metastases. 
Initial experiments demonstrated that IC H1299 cells colo-
nized approximately 50% of the hind limbs of challenged mice 
and produced osteolytic lesions (data not shown). This degree 
of penetrance was not sufficient for further experiments, and 
therefore we isolated and expanded H1299 cells from a bone 
metastasis to select a cell with more osteolytic bone metastatic 
characteristics. This isolate was termed H1299Luc and dem-
onstrated greater penetrance, exhibiting skeletal metastasis in 
100% of hind limbs of all challenged mice, which was suit-
able for pharmacology studies. Skeletal tumor colonization 
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FIGURE 1.  Radiograph, bioluminescent imaging, and TRAP histochemical staining of H1299 and H1975 NSCLC bone metas-
tases in vivo. Radiographs (×2 magnification) confirmed the presence of tumor-induced osteolysis shown by red arrows. In 
vivo monitoring of intracardiac-challenged mice was performed by BLI. Tumor bioluminescence is present in the long bones of 
the hind limbs and mandibular regions. Metastatic growth of both NSCLC models was limited to the skeleton as indicated by 
BLI, with no overt metastases to other tissues/organs. The color scale indicates the intensity of the BLI signal. TRAP5b-stained 
histological bone sections (×40 magnification) depict brown/purple TRAP-positive osteoclasts at the tumor-bone interface as 
indicated by arrows. In the histology image, T indicates tumor cells and B indicates bone tissue. Each of the above analyses per-
formed on experimental day 19 for H1299Luc and day 27 for H1975Luc. BLI, bioluminescent imaging; TRAP, tartrate-resistant 
alkaline phosphatase; NSCLC, non–small-cell lung cancer.
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and growth was particularly aggressive, such that tumor foci 
could be observed in hind limbs by BLI as early as 2 days 
post-tumor challenge. H1299Luc-challenged mice progressed 
rapidly to produce osteolytic lesions characterized by the 
presence of numerous osteoclasts at the tumor/bone interface 
(Fig. 1). Mice challenged with a second human NSCLC line, 
H1975Luc, also exhibited a high frequency of osteolytic hind 
limb bone metastasis (Fig. 1).
Metastatic growth of both NSCLC models was lim-
ited to the skeleton, with predominant occurrence in the 
long bones and jaw and no overt metastases to other tissues/
organs (Fig. 1). Earlier detectable osteolytic lesions (data not 
shown) and a higher extent of osteolysis were observed in 
 H1299Luc-challenged mice compared with H1975Luc (Fig. 1), 
indicating that these two NSCLC cell lines have distinct and 
overlapping bone colonization and growth characteristics.
Inhibition of RANKL–Blocked NSCLC-Induced  
Osteolysis
To examine the effect of osteoclast activity in the 
NSCLC-induced bone destruction and skeletal colonization or 
progression of metastases, mice bearing bone metastases from 
NSCLC were treated with the RANKL inhibitor OPG-Fc. 
Pilot BLI experiments indicated that NSCLC bone metastases 
were established 7 days after challenge with either H1299Luc 
or H1975Luc cells. To test the effect of RANKL inhibition on 
both the early stages of bone metastatic colonization and the 
progression of established bone metastasis, mice were treated 
with OPG-Fc on day 1 post-tumor challenge (preventive pro-
tocol) or on day 7 post-tumor challenge (established treatment 
protocol). Treatment of animals with OPG-Fc in both the 
highly osteolytic H1299Luc and the less osteolytic H1975Luc 
models eliminated all radiographic evidence of osteolytic 
lesions, irrespective of the protocol used (preventive or estab-
lished treatment) (p < 0.00001 versus PBS treatment for all; 
Fig. 2A, B). The prevention of local, tumor-induced osteoly-
sis by OPG-Fc was correlated with a significant reduction in 
systemic osteoclast function, as measured by sTRAP5b levels 
(p < 0.00001 for all versus PBS treatment; Fig. 2C, D).
Treatment with OPG-Fc either early (preventive proto-
col) or late (established treatment protocol) was also shown to 
significantly reduce the growth of H1299Luc tumors in bones 
as measured by both longitudinal BLI measurements and histo-
logical assessment at study end point. At the conclusion of the 
study (day 19 post-tumor challenge), reductions in the skeletal 
tumor growth rate measured by BLI were 77% and 67% in the 
preventive (day 1) and established (day 7) OPG-Fc–treatment 
groups, respectively (p < 0.001 for both; Fig. 3A). These results 
were confirmed by histological assessment: OPG-Fc treat-
ment beginning 1 day after tumor challenge resulted in a 72% 
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FIGURE 2.  RANKL inhibition completely blocked non–small-cell lung cancer–induced osteolytic bone lesions. Radiograph 
osteolytic lesion area was quantified from femurs and tibia on day 19 post-tumor challenge (A; H1299Luc) and day 27 
 post-tumor challenge (B; H1975Luc). OPG-Fc treatment beginning on day 1 (preventive) or day 7 (established tumor treat-
ment) post-tumor challenge inhibited radiographically evident tumor-induced osteolysis as compared with PBS. The data 
represent the mean lesion area/mouse + SEM. Statistical analysis performed with JMP7 using Dunnett’s test (*****p < 0.00001). 
RANKL inhibition reduces sTRAP5b, a systemic marker of osteoclasts, in H1299Luc (C) and H1975Luc (D) bone metastases 
models. Serum samples were collected at the time of necropsy and frozen at −80°C. Serum TRAP5b levels were measured by 
enzyme-linked immunoassay. The data represent the mean concentration + SEM. Statistical analysis performed with JMP7 using 
Dunnett’s test (*****p < 0.00001). PBS, phosphate-buffered saline; OPG-Fc, osteoprotegerin-Fc; RANKL, RANK ligand; sTRAP5b, 
serum tartrate-resistant alkaline phosphatase 5b; SEM, standard error of the mean.
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reduction in skeletal tumor burden (p < 0.01), and the treat-
ment of established skeletal tumors (day 7 initiation) resulted 
in a 63% reduction (p < 0.01; Fig. 3B).
Although the overall skeletal tumor burden was lower 
in the less osteolytic H1975Luc model as compared with 
the H1299Luc model, similar responses were observed after 
RANKL inhibition in the two models. Among  OPG-Fc–treated 
H1975Luc-bearing mice, skeletal growth rate reductions 
measured by BLI on day 27 were 68% (p < 0.05) and 63% 
(p = 0.053) with the preventive or established treatment proto-
cols, respectively (Fig. 3C). Histological analyses confirmed 
the reductions in skeletal tumor burden with OPG-Fc–treated 
mice compared with controls. OPG-Fc treatment in the pre-
vention protocol, beginning 1 day after tumor challenge, 
resulted in a 70% reduction in tumor burden (p < 0.05), and in 
the established treatment protocol (initiated at day 7) yielded 
a 75% reduction (p < 0.05; Fig. 3D).
Treatment with OPG-Fc had no effect on the growth 
of either H1299Luc tumors (p = 0.11) or H1975Luc tumors 
(p = 0.18) when tested in the nonosseous, subcutaneous setting 
(see Supplemental Figure 1, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A503, demonstrating that RANKL 
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FIGURE 3.  RANK ligand inhibition (preventive and established treatment protocols) reduced progression of NSCLC skeletal 
tumors. OPG-Fc treatment began on day 1 or day 7 post-tumor challenge, and bioluminescent images were captured twice 
weekly beginning on day 6 post-tumor challenge. A and B, H1299Luc NSCLC bone metastasis model. (A) BLI data for hind limb 
regions are combined values from dorsal and ventral images. Data are plotted as the mean ± SEM. The BLI signal from mice 
treated with OPG-Fc beginning on day 1 or day 7 was significantly reduced (77% and 67% TGI, respectively) relative to PBS (***p 
< 0.001 for both). B, OPG-Fc treatment significantly reduced histological intrabone tumor area using both the preventive and 
established treatment protocol (72% and 63% TGI, respectively) relative to PBS (**p < 0.01 for both). Hematoxylin-stained sections 
of each metastatic femur and tibia were histologically assessed for tumor burden using Osteo II software (Bioquant, Nashville, TN); 
the data represent the mean tumor area + SEM. Statistical analysis performed with JMP7 using Dunnett’s test. C and D, H1975Luc 
NSCLC bone metastasis model. C, The BLI signal from mice treated with OPG-Fc was significantly reduced relative to PBS begin-
ning on day 1 (68% TGI, *p < 0.05) and markedly beginning on day 7 (63% TGI, †p = 0.053). Data for hind limb regions are 
combined values from dorsal and ventral images. Data are plotted as the mean ± SEM. D, OPG-Fc treatment significantly reduced 
histological intrabone tumor area by 70% (*p < 0.05) and 75% TGI (*p < 0.05) using both the preventive and established treat-
ment protocol, respectively. Hematoxylin-stained sections of each metastatic femur and tibia were histologically assessed for tumor 
burden using Osteo II software (Bioquant); the data represent the mean tumor area + SEM. Statistical analysis performed with 
JMP7 using Dunnett’s test. ROI, regions of interest; PBS, phosphate-buffered saline; OPG-Fc, osteoprotegerin-Fc; NSCLC, non–
small-cell lung cancer; BLI, bioluminescent imaging; TGI, tumor growth inhibition; SEM, standard error of the mean.
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inhibition had no effect on growth of H1299Luc or H1975Luc 
tumors), which supports the notion that the observed effect of 
RANKL inhibition on skeletal tumor growth is indirect and 
occurs through effects on the bone microenvironment.
Combination Effects of RANKL Inhibition  
with Docetaxel Treatment on Established  
NSCLC Bone Metastases
In this article, we examined the in vivo effects of the 
RANKL inhibitor, OPG-Fc, in combination with docetaxel 
on tumor-induced osteolysis, tumor burden, and survival in 
the H1299Luc mouse model of NSCLC metastasis in bone. 
Testing was performed in the H1299Luc model, as H1299 
cells do not express functional RANK at the cell surface 
(see Supplemental Figure 2, Supplemental Digital Content 
2, http://links.lww.com/JTO/A504, showing lack of surface 
RANK expression on H1299 cells), allowing an exclusive 
testing of the indirect anti-tumor hypothesis. We used mice 
with established bone metastases to more closely mimic the 
clinical setting of a patient with existing bone metastases.
Compared with the vehicle control regimen, treatment 
of mice with established H1299Luc NSCLC bone metasta-
ses with all active agents resulted in a significant reduction 
(p < 0.0001 for all treatment groups versus vehicle control 
cohort) in skeletal tumor burden as assessed by BLI (Fig. 4A). 
Treatment with OPG-Fc as a single agent resulted in an 84.1% 
tumor growth inhibition compared with vehicle control at 
the termination of the study (day 21) (Fig. 4A). Docetaxel 
(35 mg/kg) as a single-agent treatment resulted in a signifi-
cantly lower skeletal tumor burden as early as 3 days postini-
tiation of therapy, culminating in a 96.5% reduction in skeletal 
tumor by day 21 post-tumor challenge (Fig. 4A). The great-
est reduction in skeletal tumor burden was observed with the 
combination treatment of OPG-Fc and docetaxel (35 mg/kg) at 
day 21 (99.7% tumor growth inhibition) compared with either 
docetaxel alone (p < 0.001) or OPG-Fc alone (p < 0.001) 
(Fig. 4A). Histological analysis of skeletal tumor burden area 
provided independent confirmation that all treatment groups 
experienced significant reductions compared with vehicle 
control in hind limb skeletal tumor area at day 21 (p < 0.0001 
for each group; Fig. 4B). In contrast to BLI measurements, the 
limited sensitivity of histological analysis was perhaps insuf-
ficient to demonstrate differences between treatment groups.
RANKL inhibition by means of OPG-Fc completely 
prevented the development of osteolytic bone lesions as a 
single agent, consistent with the above results, and also when 
combined with docetaxel (Fig. 5A, B). The significant reduc-
tion in the systemic osteoclast marker sTRAP5b (p < 0.0001) 
(Fig. 5C) and in TRAP-positive osteoclasts localized at the 
tumor/bone interface (Fig. 5D) after OPG-Fc treatment was 
consistent with the marked effect on radiographically evi-
dent NSCLC-induced bone lesions. Docetaxel as a single 
agent also significantly reduced the size of osteolytic lesions 
(p < 0.0001) (Fig. 5A), but did not prevent their occur-
rence (Fig. 5A, B). Although the sTRAP5b levels in the 
 docetaxel-treated group were significantly reduced com-
pared with sTRAP5b levels in vehicle control group 
(p < 0.001), these levels remained significantly increased 
*** * *** * *** *
** **** *
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B
FIGURE 4.  The combination of OPG-Fc plus docetaxel 
reduces skeletal tumor progression to a greater extent com-
pared with either single treatment. A, Mice were injected 
with 1 × 106 H1299Luc cells into the cardiac left ventricle 
on day 0. Bioluminescent images were captured twice 
weekly beginning on day 2 post-tumor challenge. Day 5 
hind limb BLI measurements were used to distribute mice 
into normalized groups for treatment. Treatment began 
on day 5. Data are the BLI value (photons/second) from 
combined dorsal and ventral images of the hind limb ROI 
and represent the mean ± SEM. The skeletal tumor bur-
den, as measured by BLI signal, was significantly reduced 
in all active treatment groups relative to the PBS groups 
(all groups ****p < 0.0001 versus PBS). OPG-Fc treatment, 
either alone or in combination with docetaxel, effectively 
reduced the skeletal progression of established lung cancer 
bone metastases. The combination of OPG-Fc/docetaxel  
at 35 mg/kg was superior to docetaxel alone or OPG-Fc 
alone (***p < 0.001 for both). B, OPG-Fc and docetaxel, 
alone or in combination, significantly reduced histological 
intrabone tumor area. Hematoxylin-stained sections of each 
metastatic femur and tibia were histologically assessed for 
tumor burden using Osteo II software (Bioquant, Nashville, 
TN). The data represent the mean tumor area + SEM. 
Statistical analysis performed with JMP7 using Dunnett’s 
test. All treatment groups resulted in a significant reduction 
in histological tumor burden ****p < 0.0001 versus  
PBS-treated group. The greater sensitivity of BLI demon-
strated differences between treatment groups, whereas the 
limited sensitivity of histological analysis was not sufficient 
to demonstrate differences between treatment groups. 
DTX, docetaxel; OPG-Fc, osteoprotegerin-Fc;  
ROI, regions of interest; BLI, bioluminescent imaging;  
PBS,  phosphate-buffered saline; SEM, standard error of  
the mean.
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above age-matched naïve nontumor challenged mice 
(p < 0.05) (Fig. 5C). Treatment with OPG-Fc, either alone or in 
combination with docetaxel, significantly reduced sTRAP5b 
relative to both age-matched naïve and vehicle tumor–chal-
lenged control mice (p < 0.0001; Fig. 5C).
OPG-Fc Treatment Improved Survival of Mice 
with Established NSCLC Bone Metastases
Among mice with established bone metastases treated 
from day 5 until the end of study, Kaplan–Meier survival 
curves demonstrated a significant improvement in survival 
upon treatment with OPG-Fc alone, docetaxel alone, and the 
combination of OPG-Fc with docetaxel (Fig. 6). Although the 
median survival time for mice bearing established H1299Luc 
NSCLC bone metastases in the vehicle control group was 
26 days, OPG-Fc treatment led to a 15% increase in survival 
(p < 0.05 versus PBS) to a median of 30 days. Treatment 
of  tumor-bearing mice with docetaxel increased survival to 
31 days (p < 0.01 versus PBS). The combination of OPG-Fc 
with docetaxel prolonged survival to a median survival of 40 
days, which was significantly greater compared with docetaxel 
treatment alone (p < 0.05 versus docetaxel alone) or OPG-Fc 
alone (p < 0.001 versus OPG-Fc alone).
DISCUSSION
Bone metastasis is observed in a high fraction (approx-
imately 40%) in advanced NSCLC, and resulting skeletal 
complications may be related to a poor prognosis.22–24 In 
this study of two NSCLC models, we have demonstrated 
the critical operative effect of RANKL not only in osteo-
clast-mediated bone destruction but also in the development 
and progression of skeletal tumors and associated survival 
outcomes.
Tumor cells metastatic to the bone use a wide variety 
of signals to alter the tumor microenvironment, leading to 
an increased RANKL:OPG ratio and subsequent increases 
in osteoclast differentiation, survival, and activation and 
bone destruction.25 This diversity of signals reflects multiple 
*** *
*** *
*** *
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FIGURE 5.  OPG-Fc and docetaxel treatments inhibited tumor-induced osteolysis of H1299Luc non–small-cell lung skeletal 
tumors through distinct mechanisms. OPG-Fc and/or docetaxel treatment began on day 5 post-tumor challenge. A, Radiograph 
lesion area was determined from femurs and tibia at day 21 post-tumor challenge. The data represent the mean lesion area/
mouse + SEM. Statistical analysis was performed with JMP7 using Dunnett’s test. All treatment groups resulted in a significant 
reduction in osteolytic lesion area, ****p < 0.0001. B, Digital radiographs (×2 magnification) depicting tumor-induced osteolysis 
(red arrows). C, Serum samples were collected at the time of necropsy and sTRAP5b levels were measured by enzyme-linked 
immunoassay. The data represent the mean concentration + SEM. Statistical analyses were conducted in SAS 9.3. Three sepa-
rate analyses were conducted taking into account data normality and group variances homogeneity. For naïve versus vehicle, 
Wilcoxon rank-sum test was used. For Treatment versus vehicle analysis, an analysis of variance model allowing for heteroge-
neous group variance was used to model the data, and a Dunnett’s test was used for post hoc comparison between individual 
treatment groups to vehicle. The Treatment versus naïve analysis was done separately but in a similar manner. sTRAP5b levels 
were significantly increased relative to age-matched naïve in PBS/saline and 35 mg/kg docetaxel groups (p < 0.0001 and *p < 
0.05), respectively. All treatments groups were significantly reduced relative to PBS/saline as indicated (****p < 0.0001,  
***p < 0.001). D, Histological sections of the bone were stained with TRAP5b, showing osteoclasts (as indicated by arrows) at 
the tumor-bone interface in vehicle (PBS) and docetaxel groups, and no osteoclasts in the OPG-Fc and OPG-Fc/docetaxel treat-
ment groups. The skeletal tumor mass is indicated by T. Histological images were captured from ×20 scans using an Aperio T2 
Scanscope (Aperio Corporation, Vista, CA) with an Olympus ×20/0.75. DTX, docetaxel; OPG-Fc, osteoprotegerin-Fc; sTRAP5b, 
serum tartrate-resistant alkaline phosphatase; PBS, phosphate-buffered saline; SEM, standard error of the mean.
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mechanisms, including unique signals from each different 
tumor type and heterogeneity within individual tumor types. 
Recent molecular characterizations demonstrated considerable 
complexity in NSCLC, even within well-defined histological 
subtypes.26 Considerable evidence has indicated the essential 
role of the RANKL pathway in osteoclast formation, function, 
and survival in physiological contexts and in tumor-associated 
bone diseases. However, it is important to understand whether 
this pathway is used in  NSCLC-associated bone disease, and 
previous studies in lung cancer models have been limited. In 
one study using intratibial injection of A549 NSCLC cells, 
RANKL inhibition completely blocked tumor-associated 
osteoclasts and reduced the resulting mixed osteolytic/osteo-
blastic bone lesions, whereas in a model using human lung 
squamous carcinoma (Hara) cells, neither OPG-Fc nor ZA 
reduced tumor-associated osteoclasts.11,13 These results were 
likely not because of an inability of RANKL inhibition to 
block PTHrP-mediated bone resorption (as was postulated in 
that study), but rather were likely because of a dosing sched-
ule of 2.5 mg/kg OPG-Fc, which, in our experience, may 
be inadequate (Dougall, unpublished observations). Other 
studies have confirmed that RANKL seems to be a critical 
mediator of PTHrP-induced bone resorption, including stimu-
lation of blood-ionized calcium levels, bone resorption, and 
TRAP-positive and cathepsin-K–positive osteoclasts, and 
RANKL inhibition prevented hypercalcemia associated with 
PTHrP-secreting human lung small-cell cancer tumor cells.27,28 
In the present study, using two different NSCLC cell lines, 
the ability of RANKL to affect both early colonization of the 
bone by tumor and in slowing the progression of existing bone 
metastases was demonstrated using preventive and established 
treatment protocols with OPG-Fc. We used a single dose of 
OPG-Fc, which maximally inhibits tumor-associated osteoly-
sis, to address the concepts whether RANKL inhibition would 
reduce NSCLC-associated bone destruction and associated 
skeletal tumor progression. Taken together, these preclini-
cal studies show RANKL was clearly essential for tumor-
associated osteoclastogenesis and subsequent osteolytic bone 
destruction, indicating that RANKL is a common signaling 
pathway for tumor-associated osteolysis induced by diverse 
lung cancer cells.
Recent clinical studies have tested the ability of deno-
sumab, a fully human antibody against RANKL, in reducing 
skeletal-related events in patients with solid tumors and bone 
metastases, including NSCLC.16,29,30 Importantly, in an explor-
atory analysis among 702 patients in the NSCLC subgroup 
of patients with solid tumors other than breast or prostate, 
denosumab was associated with significantly improved over-
all survival compared with ZA (9.5 versus 8.0 months; hazard 
ratio, 0.78 [95% confidence interval, 0.65–0.94; p = 0.01]).17 
Potential mechanisms for improved survival might include 
direct and/or indirect effects on tumor cells. Indirect effects 
could occur through osteoclast inhibition resulting in blunting 
of the vicious cycle of feedback from the bone microenviron-
ment to the tumor. In previous mouse studies of breast and 
prostate cancer bone metastases, RANKL inhibition not only 
reduced tumor-induced bone destruction but also slowed skel-
etal tumor progression,15,31 consistent with an indirect effect 
on tumor growth by means of the vicious cycle.
To address the potential of RANKL inhibition to affect 
skeletal tumor and survival responses exclusively through an 
indirect mechanism (targeting the bone microenvironment), we 
included experiments with an NSCLC cell line in the present 
study that does not express RANK (H1299). OPG-Fc, either 
alone or in combination with docetaxel, effectively reduced 
the burden of H1299Luc-induced tumors from this cell line, 
indicating an indirect anti-tumor mechanism by means of tar-
geting the bone microenvironment and an interruption of the 
vicious cycle. Furthermore, RANKL inhibition was also asso-
ciated with an increase in survival for mice with existing bone 
metastases, consistent with increase in survival for patients 
with NSCLC bone metastasis treated with the anti-RANKL 
antibody, denosumab, suggesting that the overall survival ben-
efit may be partially owing to a decrease in skeletal tumor bur-
den.17 It is important to note, however, that ethical guidelines 
for the mouse studies obligated an operational definition of 
survival as a composite of death with additional surrogates 
such as hind limb paralysis, excessive morbidity, or at least 
20% weight loss, potentially impacting its translation to the 
human clinical study results. The observation that OPG-Fc 
treatment had no effect on H1299 and H1975 tumors grown in 
a nonosseous environment is also consistent with an indirect 
anti-tumor mechanism, through osteoclast suppression.
In addition to the well-established indirect anti-tumor 
benefit of RANKL inhibition in bone metastases, a functional 
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FIGURE 6.  RANK ligand inhibition in mice with established 
non–small-cell lung cancer bone metastasis is associated with 
prolonged survival. OPG-Fc and/or docetaxel (DTX) treat-
ment began on day 5 post-tumor (H1299Luc) challenge. 
Mice with established bone metastases on treatment were 
monitored until death or until they became moribund, expe-
rienced hind limb paralysis, or 20% weight loss (operative 
definition of survival), at which point the mice were eutha-
nized. The Kaplan–Meier plot shows significant improve-
ment in survival with OPG-Fc alone or in combination with 
DTX. The OPG-Fc group showed a 15% increase in survival 
(time to moribund state) compared with the PBS control 
(p < 0.05; n = 10 per group). Median survival times were 
26 days for PBS and 30 days for OPG-Fc. OPG plus DTX at 
35 mg/kg significantly increased survival compared with DTX 
at 35 mg/kg alone (p < 0.05; n = 10 per group) or OPG-Fc 
alone (p = 0.001). Median survival times were 31 days for 
DTX and 40 days for OPG-Fc plus DTX at 35 mg/kg. OPG-Fc, 
 osteoprotegerin-Fc; PBS, phosphate-buffered saline.
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role for the RANKL receptor, RANK, on tumor cells has been 
defined experimentally for breast and prostate cancer cells, 
leading to increased tumorigenesis or metastasis through direct 
action of RANKL.25 RANKL promotes tumor formation and 
facilitates the migration and invasion of  RANK-expressing 
tumor cells. This may be particularly relevant in metastasis to 
the bone, lymph nodes, or other distant sites, as the bone and 
lymph node stroma are a rich source of RANKL. Preliminary 
immunohistochemical analysis of RANK and RANKL expres-
sion on primary human NSCLC adenocarcinomas by our group 
has indicated that RANK and RANKL expression can be fre-
quently observed (56% and 75%, respectively; Branstetter 
et al., manuscript in preparation). Although RANK expression 
is observed in approximately 50% of human lung cancer cell 
lines (Tometsko, Dougall data not shown) and expression of 
RANK on NSCLC has been reported to increase migration and 
expression of intercellular adhesion molecule-1 in a RANKL-
dependent manner in vitro, we demonstrated here that RANK-
negative (H1299) NSCLC will efficiently metastasize to the 
bone, indicating that RANK expression is not required for 
bone metastases.32 These data suggest that RANKL inhibition 
may affect NSCLC tumor growth in the skeleton potentially 
by indirect mechanisms (as defined in the present studies) and 
direct mechanisms. Ongoing research is exploring the role 
of functional expression of RANK on tumor cells in promot-
ing tumor progression and/or metastatic activity, and whether 
RANKL inhibition will provide additional benefits in NSCLC 
specifically.
Because the reduction in skeletal tumor burden achieved 
with RANKL inhibition has been shown to be additive when 
combined with chemotherapy, hormonal therapy, or targeted 
therapies in models of breast and prostate cancer bone metasta-
sis, we addressed whether similar combination effects could be 
obtained in NSCLC bone metastases.18,31 RANKL inhibition 
targeting the bone microenvironment through osteoclast reduc-
tion was combined with docetaxel, a standard of care treatment 
in NSCLC that is directly cytotoxic without any effects on sys-
temic osteoclast activity. Given that docetaxel treatment had 
no apparent effect on osteoclasts localized at the tumor/bone 
interface but did significantly reduce skeletal tumor burden, 
the ability of docetaxel to reduce sTRAP5b measures and the 
size of radiographically evident  NSCLC-induced bone lesions 
was likely a result of reduced tumor burden and not a direct 
effect on osteoclast activity. By using the sensitive tumor-
imaging modality BLI, we showed that combination treatment 
with two agents having distinct mechanisms of action, OPG-Fc 
and docetaxel, reduced skeletal tumor burden to a significantly 
greater extent compared with either agent alone.
In conclusion, these preclinical studies define a critical 
role of RANKL pathway in NSCLC osteolytic bone metasta-
sis. The present study also provides evidence supporting an 
anti-tumor benefit of RANKL inhibition in NSCLC at least 
through indirect mechanisms, through inhibition of pathologic 
bone resorption. These preclinical studies may also provide 
mechanistic insight into the clinical studies demonstrating 
the ability of denosumab to not only decrease skeletal-related 
events in NSCLC patients with bone metastases but also 
increase survival.16,17 We showed, in two novel mouse models 
of NSCLC-induced bone metastases, that RANKL inhibi-
tion significantly reduced destructive osteolysis and skeletal 
tumor burden, and was associated with a survival advantage. 
Furthermore, the observation that combining RANKL inhibi-
tors with chemotherapy provided an even greater benefit com-
pared with either agent alone demonstrates the potential of 
targeting the bone environment to enhance the benefit of can-
cer therapies and supports further clinical evaluation.
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